GlaxoSmithKline and Theravance have launched Breo Ellipta, a once-daily prescription medicine for chronic obstructive pulmonary disease (COPD), in pharmacies throughout the U.S. Breo Ellipta is a combination of the inhaled corticosteroid (ICS), fluticasone furoate “FF”, and the long-acting beta2-agonist (LABA), vilanterol “VI” (FF/VI 100/25 mcg). It is indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including c...